A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.
Jeremy B FooteTyler E MattoxAdam B KeetonXi ChenForrest T SmithKristy L BerryThomas HolmesJunwei WangChung-Hui HuangAntonio B WardCherlene HardyKarrianne G FletenKjersti FlatmarkKarina J YoonSujith SarveshPuranchandra Nagaraju GanjiYulia MaxuitenkoJacob ValiyaveettilJulienne L CarstensDonald J BuchsbaumJennifer YangGang ZhouElmar NurmemmedovIvan BabicVadim GaponenkoHazem AbdelkarimAmit K MitraMichael R BoydUpender ManneSejong BaeBassel F El-RayesGary A PiazzaPublished in: bioRxiv : the preprint server for biology (2024)
It is projected that colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDA) will cause 52,580 and 49,830 deaths in the US in 2023, respectively (1). The 5-year survival rates for CRC and PDA are 65% and 12%, respectively (1). Over 50% of CRC and 90% of PDA patients harbor mutations in KRAS genes that are associated with poor prognosis, making the development of novel KRAS inhibitors an urgent unmet medical need (2).
Keyphrases
- poor prognosis
- long non coding rna
- wild type
- end stage renal disease
- ejection fraction
- healthcare
- mouse model
- papillary thyroid
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- genome wide
- climate change
- gene expression
- young adults
- dna methylation
- transcription factor
- childhood cancer
- lymph node metastasis